|
|
|
|
|
by raylad
606 days ago
|
|
This treatment does not in fact prevent HIV infection. It prevents infected cells from producing viable virus particles. Because of this, it seems very likely that if any patient being treated with this drug ever discontinued it, they could develop HIV quickly from cells that were already infected in their body that had been suppressed from producing virus particles but were no longer suppressed. I was not able to find, in a little searching, any study at all on whether cells infected during treatment survive or are somehow cleared by the immune system or undergo apoptosis. Without this information it seems highly irresponsible to claim that this is a method of preventing HIV infection. |
|
Lenacapavir interferes "with multiple essential steps of the viral lifecycle, including capsid-mediated nuclear uptake of HIV-1 proviral DNA (by blocking nuclear import proteins binding to capsid), virus assembly and release (by interfering with Gag/Gag-Pol functioning, reducing production of capsid protein subunits), and capsid core formation (by disrupting the rate of capsid subunit association, leading to malformed capsids)" [1].
For comparison, tenofovir diphosphate (from Descovy) "inhibits the activity of HIV reverse transcriptase and causes DNA chain termination after getting incorporated into the viral DNA" [2].
Descovy thus works at stage 3 (reverse transcription); Lenacapavir works at stages 3 (integration), 6 (assembly) and 7 (budding) [3].
> it seems very likely that if any patient being treated with this drug ever discontinued it, they could develop HIV quickly from cells that were already infected in their body
HIV-uninhibted T cells should be fine clearing these out. IT would be more surprising to see the cells stick around after having been infected.
[1] https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e56...
[2] https://www.clinicaltrialsarena.com/projects/descovy-emtrici...
[3] https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-li...